R-2A Activity · President's Budget PB2027

8) Vaccine Acceleration By Modular Progression - Enhanced Biological Defense (VAMP-ENBD)

Activity a7·Project PT4 — Protect (ACD&P)·PE 0603884BP·Defense-Wide
FY2027 Request
$31.1M
▼ 42% vs FY2026
HitchAI read

This activity requests $31.1M in FY2027, 24% of project PT4, down 42% on FY2026. The R-2A exhibit describes it across FY2025–FY2027, including what the FY2027 money is planned to buy.

FY2027 Request
$31.1M
▼ 42% vs FY2026
FY2026 Enacted
$53.3M
▲ 6.2% vs FY2025
FY2025 Actual
$50.2M
Prior year
Planned work

What the FY2027 request buys

Verbatim from the R-2A exhibit for project PT4 of PE 0603884BP. This is the budget justification's own description of work that has not happened yet — the one thing no other level of the budget carries.

FY2027 planned work

Continue development and manufacturing of multiple vaccine candidates against biothreats. Continue test and evaluation efforts in safety and efficacy clinical trials.

FY2026 to FY2027 change

FY 2026 to FY 2027 decrease is due to fewer additional manufacturing and clinical trial efforts compared to FY 2026.

Before the request year

FY2025–FY2026: what came before

Prior-year accomplishments and current-year plans from the same exhibit. Context for the FY2027 plan, not a series — an activity partitions its project exactly in the request year, but can under-cover it in earlier years.

FY2026 plans — current year

Continue development and manufacturing of multiple vaccine candidates against biothreats. Continue test and evaluation efforts in safety and efficacy clinical trials. Add manufacturing and clinical trials for plague vaccine.

FY2025 accomplishments

Continued development and manufacturing of vaccine candidates against multiple biothreats. Continued test and evaluation efforts in safety and efficacy clinical trials. Initiated several clinical trials.

Money

Three years, and no five-year plan

An R-2A activity publishes the prior year, the current year and the budget year. The FYDP outyears exist at project and program-element level and are deliberately absent here rather than inferred. Estimate types are colored and never summed into one figure.

2550050.2FY25ACTUAL53.3FY26ENACTED31.1FY27REQUEST
Actual Enacted Request
Fiscal YearEstimate TypeAmount ($M)
FY2025Actual50.2
FY2026Enacted53.3
FY2027Request31.1

This activity is 24% of project PT4's FY2027 request and 8.0% of PE 0603884BP's. In the request year the activities under a project sum to it exactly; in the current year they under-cover it in about 9% of cases, so an activity's delta can legitimately exceed its parent's and the two must not be compared row to row.

Where this sits

10 activities in project PT4

Every R-2A line of this project, largest FY2027 request first. Linked where the activity has enough of its own narrative to carry a page; the rest are shown in full on the project page.

3) Generative Unconstrained Intelligent Drug Engineering - Enhanced Biological Defense (GUIDE-ENBD)$45.5M ▼ 25%1) Accelerated Antibodies - Enhanced Biological Defense (AA-ENBD)$32.1M ▲ 19%
8) Vaccine Acceleration By Modular Progression - Enhanced Biological Defense (VAMP-ENBD) — this activity$31.1M ▼ 42%
5) Medical Countermeasures Platform Technologies (MCMPT) - Host Directed Countermeasure$9.0M ▲ 20%
7) Prophylactic Technology Systems (ProTecS)$7.3M NEW
4) Medical Countermeasures Platform Technologies (MCMPT) - Prevention Platform$3.8M ▲ 21%
6) Plague Monoclonal Antibodies (PLG MAB)$0.5M ▼ 92%
2) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD)▼ 100%
9) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD)
10) Shipboard Isolation System (SIS)
Source
FY2027 Office of the Secretary of Defense RDT&E Budget Justification · Exhibit R-2A · PE 0603884BP, project PT4 (President's Budget PB2027). Congressional marks are recorded on the program element, never on an activity.
Machine access
Markdown twin /programs/0603884BP/PT4/a7.md · MCP mcp.hitchintel.combudget_get_activity